DNA Entering Transition and Monmouth Medical Center, in Partnership with LifebankUSA(R), Launches Program for Placental and Cord Blood Stem Cell Banking

Share: 

City of Industry, CA --(www.USEquityNews.com)-- 12/13/2007 - Pharmaceutical industry alert provided by U.S. Equity News. Genentech, Inc. (NYSE: DNA) is one of the world's largest biotechnology companies. Genentech's core technology focus is in the area of oncology, but the company develops and markets products for the treatment of cardiovascular diseases, respiratory and endocrine disorders, inflammatory and immune problems, and neurological disorders. Growth is beginning to slow now that biologic blockbusters Rituxan, Avastin, and Herceptin are slowing


Ceregene, Inc. (NASDAQ: CEGE) recently presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration.

Monmouth Medical Center, an affiliate of the Saint Barnabas Health Care System, recently announced that its Department of Obstetrics and Gynecology has established a partnership with LifebankUSA, a New Jersey-based stem cell banking service, to establish the Monmouth Medical Center-LifebankUSA PlacentaCord Banking Program. The new program, south Jersey's first hospital affiliated program for banking both placenta-derived and cord blood stem cells, will educate expectant parents regarding stem cell banking services when giving birth at the Medical Center. LifebankUSA, based in Cedar Knolls, N.J., and a division of Summit-based Celgene Corporation (NASDAQ: CELG), is an AABB-accredited, ISO-certified stem cell banking service.

Aida Pharmaceuticals (OTCBB: AIDA) recently announced that the company's upcoming Rh-Apo2L cancer drug has been named as a "New and High-Tech Transforming Products of 2007" by the Shanghai New High Technology Service Centre ("SNHTSC"), a special government commercialization division led by the Shanghai Municipal Government. This designation will allow Rh-Apo2L to have preferential policies during the commercialization process after Aida completes China's State Food and Drug Administration ("SFDA") clinical testing of the product. The stated role of the SNHTSC, according to its website http://www.hitec.net.cn, is to be a clearinghouse that allows the Chinese government to evaluate and narrow down technology candidates that have the greatest potential for national and global commercialization.

About U.S. Equity News

U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.

U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.

Contact Information:
U.S. Equity News
Tel: (626) 961-8039
Email: info@usequitynews.com

Comments:
Disclaimer: User Comments do not reflect the views of US Equity News, and we are not responsible for the content of users' comments. We also reserve the right to edit or delete comments to our discretion.

---